UY37656A - Compuestos que inhiben la proteína mcl-1 - Google Patents
Compuestos que inhiben la proteína mcl-1Info
- Publication number
- UY37656A UY37656A UY0001037656A UY37656A UY37656A UY 37656 A UY37656 A UY 37656A UY 0001037656 A UY0001037656 A UY 0001037656A UY 37656 A UY37656 A UY 37656A UY 37656 A UY37656 A UY 37656A
- Authority
- UY
- Uruguay
- Prior art keywords
- compounds
- mcl
- protein
- inhibit
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
En la presente se proveen inhibidores de la proteína leucemia de células mieloides 1 (Mcl-1), métodos para su preparación, composiciones farmacéuticas relacionadas, y métodos de uso de esto. Po ejemplo, en la presente se proveen compuestos de Fórmula I, o un estereoisómero de estos; y sales farmacéuticamente aceptables de estos y composiciones farmacéuticas que contienen los compuestos. Los compuestos y composiciones provistas en la presente pueden usarse, por ejemplo, en el tratamiento de enfermedades o afecciones, como cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762479230P | 2017-03-30 | 2017-03-30 | |
| US201762479171P | 2017-03-30 | 2017-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY37656A true UY37656A (es) | 2018-10-31 |
Family
ID=61972255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001037656A UY37656A (es) | 2017-03-30 | 2018-04-02 | Compuestos que inhiben la proteína mcl-1 |
Country Status (33)
| Country | Link |
|---|---|
| US (5) | US10300075B2 (es) |
| EP (1) | EP3601297B9 (es) |
| JP (2) | JP6453507B2 (es) |
| KR (1) | KR102372322B1 (es) |
| CN (1) | CN110691784B (es) |
| AU (2) | AU2018244349B2 (es) |
| BR (1) | BR112019020459B1 (es) |
| CA (1) | CA3057882A1 (es) |
| CL (1) | CL2019002777A1 (es) |
| CO (1) | CO2019011762A2 (es) |
| CR (1) | CR20190489A (es) |
| DK (1) | DK3601297T5 (es) |
| ES (1) | ES2940641T3 (es) |
| FI (1) | FI3601297T3 (es) |
| HR (1) | HRP20221412T2 (es) |
| HU (1) | HUE060919T2 (es) |
| IL (1) | IL269603B (es) |
| JO (1) | JOP20190229B1 (es) |
| LT (1) | LT3601297T (es) |
| MX (1) | MX2019011693A (es) |
| NZ (1) | NZ757606A (es) |
| PE (1) | PE20200335A1 (es) |
| PH (1) | PH12019502245A1 (es) |
| PL (1) | PL3601297T3 (es) |
| PT (1) | PT3601297T (es) |
| RS (1) | RS63892B9 (es) |
| SA (1) | SA519410222B1 (es) |
| SG (1) | SG11201908945RA (es) |
| SI (1) | SI3601297T1 (es) |
| TW (1) | TWI685493B (es) |
| UA (1) | UA124784C2 (es) |
| UY (1) | UY37656A (es) |
| WO (1) | WO2018183418A1 (es) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3570844T3 (pl) | 2017-01-20 | 2024-02-26 | Arcus Biosciences, Inc. | Azolopirymidyna do leczenia zaburzeń związanych z nowotworami |
| AU2018243770A1 (en) | 2017-03-30 | 2019-09-19 | F. Hoffmann-La Roche Ag | Isoquinolines as inhibitors of HPK1 |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| JOP20180029A1 (ar) | 2017-03-30 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب حلقي غير متجانس |
| EP3668878A1 (en) * | 2017-08-18 | 2020-06-24 | Amgen Inc. | Compounds that inhibit mcl-1 protein |
| EP3676270A1 (en) | 2017-08-29 | 2020-07-08 | Amgen Inc. | Macrocyclic compounds that inhibit mcl-1 protein |
| US11301560B2 (en) * | 2018-02-09 | 2022-04-12 | Bolster, Inc | Real-time detection and blocking of counterfeit websites |
| US11271966B2 (en) * | 2018-02-09 | 2022-03-08 | Bolster, Inc | Real-time detection and redirecton from counterfeit websites |
| US11478479B2 (en) | 2018-02-16 | 2022-10-25 | Arcus Biosciences, Inc. | Dosing with an azolopyrimidine compound |
| US11274105B2 (en) | 2018-03-05 | 2022-03-15 | Amgen Inc. | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists |
| WO2019222112A1 (en) | 2018-05-14 | 2019-11-21 | Gilead Sciences, Inc. | Mcl-1 inhibitors |
| US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| BR112021008796A2 (pt) * | 2018-11-09 | 2021-08-03 | Prelude Therapeutics, Incorporated | derivados de espiro-sulfonamida como inibidores de proteína de leucemia-1 de células mieloides (mcl-1) |
| CN112867722B (zh) * | 2019-01-18 | 2022-09-23 | 苏州亚盛药业有限公司 | 作为mcl-1抑制剂的大螺环醚(macrocyclic spiroethers) |
| CN112204036B (zh) * | 2019-01-23 | 2022-12-27 | 苏州亚盛药业有限公司 | 作为mcl-1抑制剂的大环稠合的吡唑 |
| BR112021023229A2 (pt) | 2019-05-20 | 2022-05-31 | Servier Lab | Conjugados anticorpo-fármaco inibidores de mcl-1 e métodos de uso |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| PE20220231A1 (es) | 2019-06-25 | 2022-02-07 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso |
| AU2020309745A1 (en) | 2019-07-09 | 2022-03-03 | Janssen Pharmaceutica Nv | Macrocyclic spirocycle derivatives as MCL-1 inhibitors |
| JP7371243B2 (ja) | 2019-10-18 | 2023-10-30 | フォーティ セブン， インコーポレイテッド | 骨髄異形成症候群及び急性骨髄性白血病を治療するための併用療法 |
| CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| US11325891B2 (en) | 2019-11-26 | 2022-05-10 | Gilead Sciences, Inc. | Processes and intermediates for preparing MCL1 inhibitors |
| IL294032A (en) | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
| CA3169451A1 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
| JP2021161114A (ja) * | 2020-03-31 | 2021-10-11 | アムジエン・インコーポレーテツド | Ｍｃｌ−１化合物のメチル化 |
| US20230212191A1 (en) * | 2020-04-16 | 2023-07-06 | Prelude Therapeutics, Incorporated | Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein |
| EP4143194A1 (en) | 2020-05-01 | 2023-03-08 | Gilead Sciences, Inc. | Cd73 inhibiting 2,4-dioxopyrimidine compounds |
| WO2021225833A1 (en) | 2020-05-06 | 2021-11-11 | Amgen Inc. | Synthesis of sulfonamide intermediates |
| IL297522A (en) * | 2020-05-06 | 2022-12-01 | Amgen Inc | Synthesis of vinylic intermediates |
| TWI827924B (zh) * | 2020-05-06 | 2024-01-01 | 美商安進公司 | 大環Mcl-1抑制劑中間體的閉環合成 |
| AU2021268569A1 (en) * | 2020-05-06 | 2022-12-15 | Amgen Inc. | Synthesis of vinylic protected alcohol intermediates |
| TW202208342A (zh) | 2020-05-06 | 2022-03-01 | 美商安進公司 | 乙烯基環丁基中間體之合成 |
| AU2021271694A1 (en) * | 2020-05-13 | 2023-01-19 | Prelude Therapeutics, Incorporated | Spiro-sulfonamide derivatives as inhibitors of Myeloid Cell Leukemia-1 (MCL-1) protein |
| MX2022015813A (es) | 2020-06-10 | 2023-01-24 | Janssen Pharmaceutica Nv | 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1. |
| JP2022039996A (ja) * | 2020-08-26 | 2022-03-10 | アムジエン・インコーポレーテツド | Ｍｃｌ－１阻害剤処方物 |
| JP2023540083A (ja) | 2020-09-03 | 2023-09-21 | アムジエン・インコーポレーテツド | 求核芳香族置換によるジオールの不斉化 |
| CA3201943A1 (en) * | 2020-11-19 | 2022-05-27 | Gilead Sciences, Inc. | Processes and intermediates for preparing mcl1 inhibitors |
| JP2023553808A (ja) | 2020-11-24 | 2023-12-26 | ノバルティス アーゲー | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
| AU2021385537A1 (en) * | 2020-11-25 | 2023-06-22 | Amgen Inc. | Enantioselective alkenylation of aldehydes |
| JP2023554070A (ja) | 2020-12-17 | 2023-12-26 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１の阻害剤としての分岐３－フルオロ－ブタ－３－エナミド |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| JP2024516641A (ja) | 2021-04-26 | 2024-04-16 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１阻害剤としての大環状２－アリルテトラヒドロフラン |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
| AU2022291381A1 (en) | 2021-06-11 | 2023-11-30 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022299051A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11926628B2 (en) | 2021-06-23 | 2024-03-12 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023057484A1 (en) | 2021-10-06 | 2023-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy |
| TW202330504A (zh) | 2021-10-28 | 2023-08-01 | 美商基利科學股份有限公司 | 嗒𠯤—３（２ｈ）—酮衍生物 |
| AU2022376954A1 (en) | 2021-10-29 | 2024-05-02 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2023088894A1 (en) | 2021-11-16 | 2023-05-25 | Janssen Pharmaceutica Nv | Macrocyclic 2-amino-but-3-enamides as inhibitors of mcl-1 |
| WO2023107956A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| US20230242508A1 (en) | 2021-12-22 | 2023-08-03 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023150249A1 (en) | 2022-02-04 | 2023-08-10 | Amgen Inc. | Crystalline forms of an mcl-1 inhibitor |
| WO2023150250A1 (en) * | 2022-02-04 | 2023-08-10 | Amgen Inc. | Crystalline salt and solvate forms of murizatoclax (amg 397) |
| EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Ｋｒａｓ ｇ１２ｄ調節化合物 |
| WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US6042820A (en) | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
| US6472375B1 (en) | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
| BRPI0810365A2 (pt) | 2007-04-16 | 2014-10-29 | Abbott Lab | Inibidores de mlc-1 de indol 7-substituído |
| US20130035304A1 (en) | 2010-01-29 | 2013-02-07 | Walensky Loren D | Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders |
| US20130048221A1 (en) | 2011-08-31 | 2013-02-28 | Avery Dennison Corporation | Adhesive Acrylate-Olefin Copolymers, Methods for Producing Same and Compositions Utilizing Same |
| US9486422B2 (en) | 2011-10-06 | 2016-11-08 | The Regents Of The University Of Michigan | Small molecule inhibitors of Mcl-1 and the uses of thereof |
| ES2657649T3 (es) | 2012-03-29 | 2018-03-06 | The Regents Of The University Of Michigan | Inhibidores de Mcl-1 de molécula pequeña y sus usos |
| CA2943815C (en) * | 2014-03-27 | 2023-04-04 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
| JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| WO2017147410A1 (en) * | 2016-02-25 | 2017-08-31 | Amgen Inc. | Compounds that inhibit mcl-1 protein |
| JP6786892B2 (ja) | 2016-06-09 | 2020-11-18 | 富士ゼロックス株式会社 | サーバ装置、情報処理システム及びプログラム |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| EP3668878A1 (en) | 2017-08-18 | 2020-06-24 | Amgen Inc. | Compounds that inhibit mcl-1 protein |
| EP3676270A1 (en) | 2017-08-29 | 2020-07-08 | Amgen Inc. | Macrocyclic compounds that inhibit mcl-1 protein |
-
2018
- 2018-03-27 JP JP2018059341A patent/JP6453507B2/ja active Active
- 2018-03-28 PE PE2019001963A patent/PE20200335A1/es unknown
- 2018-03-28 PT PT187178116T patent/PT3601297T/pt unknown
- 2018-03-28 RS RS20230036A patent/RS63892B9/sr unknown
- 2018-03-28 UA UAA201910703A patent/UA124784C2/uk unknown
- 2018-03-28 HU HUE18717811A patent/HUE060919T2/hu unknown
- 2018-03-28 CR CR20190489A patent/CR20190489A/es unknown
- 2018-03-28 CN CN201880035818.3A patent/CN110691784B/zh active Active
- 2018-03-28 ES ES18717811T patent/ES2940641T3/es active Active
- 2018-03-28 JO JOP/2019/0229A patent/JOP20190229B1/ar active
- 2018-03-28 MX MX2019011693A patent/MX2019011693A/es unknown
- 2018-03-28 KR KR1020197029091A patent/KR102372322B1/ko active IP Right Grant
- 2018-03-28 AU AU2018244349A patent/AU2018244349B2/en active Active
- 2018-03-28 BR BR112019020459-8A patent/BR112019020459B1/pt active IP Right Grant
- 2018-03-28 EP EP18717811.6A patent/EP3601297B9/en active Active
- 2018-03-28 US US15/938,001 patent/US10300075B2/en active Active
- 2018-03-28 PL PL18717811.6T patent/PL3601297T3/pl unknown
- 2018-03-28 WO PCT/US2018/024723 patent/WO2018183418A1/en unknown
- 2018-03-28 LT LTEPPCT/US2018/024723T patent/LT3601297T/lt unknown
- 2018-03-28 NZ NZ757606A patent/NZ757606A/en unknown
- 2018-03-28 FI FIEP18717811.6T patent/FI3601297T3/fi active
- 2018-03-28 SI SI201830809T patent/SI3601297T1/sl unknown
- 2018-03-28 SG SG11201908945R patent/SG11201908945RA/en unknown
- 2018-03-28 DK DK18717811.6T patent/DK3601297T5/da active
- 2018-03-28 CA CA3057882A patent/CA3057882A1/en active Pending
- 2018-03-28 HR HRP20221412TT patent/HRP20221412T2/hr unknown
- 2018-03-30 TW TW107111110A patent/TWI685493B/zh active
- 2018-04-02 UY UY0001037656A patent/UY37656A/es unknown
- 2018-12-11 JP JP2018231352A patent/JP6629419B2/ja active Active
-
2019
- 2019-03-11 US US16/297,904 patent/US10500213B2/en active Active
- 2019-08-22 US US16/547,747 patent/US10632128B2/en active Active
- 2019-09-24 IL IL269603A patent/IL269603B/en unknown
- 2019-09-27 CL CL2019002777A patent/CL2019002777A1/es unknown
- 2019-09-27 PH PH12019502245A patent/PH12019502245A1/en unknown
- 2019-09-30 SA SA519410222A patent/SA519410222B1/ar unknown
- 2019-10-24 CO CONC2019/0011762A patent/CO2019011762A2/es unknown
-
2020
- 2020-02-06 US US16/783,269 patent/US10821115B2/en active Active
- 2020-09-23 US US17/029,249 patent/US11224601B1/en active Active
-
2021
- 2021-01-15 AU AU2021200233A patent/AU2021200233A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019011762A2 (es) | Compuestos que inhiben la proteína mcl-1 | |
| CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
| NI201900013A (es) | Inhibidor de piridopirimidinona cdk2/4/6 | |
| UY38221A (es) | Inhibidores de proteínas ras con g12c mutantes | |
| CL2019000820A1 (es) | Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134) | |
| ECSP21038390A (es) | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr | |
| BR112016028814A2 (pt) | ?composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição de reações imunitárias ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, composto, um sal, um isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, de um sal, de um isômero, ou de uma mistura farmaceuticamente aceitável do mesmo? | |
| CL2018003121A1 (es) | Inhibidores del potenciador del homólogo zeste 2. | |
| UY35275A (es) | Derivados de aminopirazina | |
| CO2020004977A2 (es) | Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa | |
| CO2019002523A2 (es) | Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica | |
| UY36758A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| CL2021001198A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| CL2020001107A1 (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3. | |
| CL2022003206A1 (es) | Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501) | |
| ECSP18056196A (es) | Derivados de indano | |
| UY38133A (es) | Nuevos inhibidores de cdk8/19 | |
| EA201992303A1 (ru) | СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1 | |
| AR120156A1 (es) | Compuestos quiméricos de somatostatina-dopamina estables de almacenamiento y las formas salinas de estos | |
| CR20150593A (es) | Potenciador de inhibidores del homólogo de zeste |